Evidence map›Paper›PMID 41826998›Full record

ArticleRespiratory research2026

Telomere damage-mediated senescence in alveolar epithelial type II cells but not in macrophages aggravates inflammation in acute lung injury.

Christina Beatrix Hildebrand, Seyma Öztürk, Jia Li Ye, Dirk Wedekind, Ulrich A Maus, Christian Bär, Christian Mühlfeld, Christina Brandenberger

Abstract read
In one paragraph

Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christina Beatrix HildebrandInstitute of Functional Anatomy, Charité-Universitätsmedizin Berlin, Philippstraße 11, 10115, Berlin, Germany.ORCID http://orcid.org/0000-0001-6139-8399
Seyma ÖztürkInstitute of Functional Anatomy, Charité-Universitätsmedizin Berlin, Philippstraße 11, 10115, Berlin, Germany.
Jia Li YeInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover, 30625, Germany.
Dirk WedekindInstitute of Laboratory Animal Science, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover, 30625, Germany.
Ulrich A MausDepartment of Experimental Pneumology, Hannover Medical School, Feodor- Lynen-Strasse 21, Hannover, 30625, Germany.
Christian BärInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover, 30625, Germany.
Christian MühlfeldInstitute of Functional and Applied Anatomy, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover, 30625, Germany.
Christina BrandenbergerInstitute of Functional Anatomy, Charité-Universitätsmedizin Berlin, Philippstraße 11, 10115, Berlin, Germany. christina.brandenberger@charite.de.ORCID http://orcid.org/0000-0001-9848-432X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severity of acute lung injury (ALI) increases with age and is associated with enhanced inflammation in older individuals (inflamm-aging), characterized by increased expression of pro-inflammatory cytokines. Telomere damage can cause irreversible cell cycle arrest, known as cellular senescence, that may promote pro-inflammatory signaling and exacerbate ALI. Therefore, we investigated the role of telomere damage-mediated senescence in alveolar epithelial type II (AEII) cells and macrophages in injury and inflammation of lipopolysaccharide (LPS)-induced ALI in mice.Cell type-specific deletion of Trf1 (telomeric repeat-binding factor 1) was achieved using tamoxifen-inducible Cre-loxP mouse models driven by the Sftpc (surfactant protein c) promoter for AEII cells or Lyz2 (lysozyme 2) promoter for macrophages to induce telomere damage in respective cell types. Mice without Trf1 deletion were used for comparison, as well as naturally aged mice. After tamoxifen injections, ALI was induced by intranasal application of 2.5 mg LPS/kg body weight. Control mice received saline. The severity of ALI, as well as cell type-specific molecular responses, were assessed using functional, immunological, histological and transcriptomic investigations.Telomere damage-mediated senescence in AEII cells resulted in an increase in inflammatory BALF cells and cytokines and a decline in lung function 72 h after LPS exposure, compared to mice without Trf1 deletion in AEII cells. Transcriptomic analysis revealed that Trf1-deleted AEII cells exhibited specific cell cycle inhibition, as well as an elevated DNA damage response (DDR), in both control and LPS-treated Sftpc-Cre mice. Trf1 deletion in macrophages triggered an augmented DDR without affecting LPS-driven lung inflammation compared to mice without Trf1 deletion. Control mice with Trf1 deletion of both Cre-loxP mouse models did not show signs of inflamm-aging. Additional comparison with old mice revealed that global aging causes a much greater severity in ALI than Trf1 deletion in lung cells.The findings demonstrate that telomere damage-mediated senescence in AEII cells promotes inflammation in the late exudative phase of ALI, while Trf1 deletion in macrophages did not cause an aggravation of ALI. The results also suggest that additional mechanisms of aging beyond pulmonary telomere damage and cellular senescence, such as global inflamm-aging, contribute to the severity of ALI in old age.

Indexed as

Acute Lung InjuryAlveolar Epithelial CellsCellular SenescenceMacrophagesMacrophages, AlveolarTelomereAnimalsDNA DamageMaleMiceMice, Inbred C57BLMice, KnockoutMice, Transgenicacute lung injuryalveolar epithelial type II cellscellular senescenceinflamm-agingmacrophagespulmonary agingtelomere distortion

Identifiers

PMID41826998
PMCPMC13063740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.